Clinical trial
Pilot Study of Docetaxel & Bevacizumab +/- Trastuzumab in First-Line Treatment…
NCT00364611 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00364611 |
|---|---|
| Title | Pilot Study of Docetaxel & Bevacizumab +/- Trastuzumab in First-Line Treatment of Patients With Metastatic Breast Cancer |
| Official title | A Pilot, Phase II, Multicenter, Open-Label, Prospective Evaluation of Docetaxel and Bevacizumab ± Trastuzumab in the First-Line Treatment of Patients With Metastatic Breast Cancer |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Bevacizumab, Docetaxel, Trastuzumab |
| Enrollment | 73 |
| Start date | Aug 1, 2006 |
| Primary completion | Jun 1, 2011 |
| Completion | Apr 1, 2012 |
| First posted | Aug 15, 2006 |
| Last update posted | Aug 23, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: